Oct 1, 2021 · Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT.

Jun 25, 2021 · Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT.

Nov 5, 2020 · Second-line therapy with pembrolizumab-GVD is a highly effective and well-tolerated regimen that can efficiently bridge pts with RR cHL to HDT/AHCT. Updated results …

Second-line pembrolizuab plus intravenous (IV) gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) led to high complete response (CR) rates in patients with …

Jun 25, 2021 · We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or …

Pembrolizumab plus GVD as SLT for cHL is associated with a CR rate of 95% and favorable toxicity profile. This regimen efficiently and safely bridged patients with rel/ref cHL to …

Nov 3, 2021 · This phase II study evaluating the efficacy and safety of pembro-GVD in patients with R/R cHL demonstrated that pembro-GVD was highly effective as second-line therapy and …

Pembrolizumab blocks PD-1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells. In this study, …

Relapse or refractory disease following 1 line of multi-agent chemotherapy (not including pembro-GVD). Eligible for high dose therapy (HDT)/ASCT. Achieved complete response (Deauville 3 …

Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin's lymphoma …